top of page


A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Paper Abstract

Phase II, single arm study of NOVOTTF-200A In bevacizumab-naive subjects with recurrent WHO grade III Malignant Astrocytoma


“This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second-line treatment and who have not previously received any BEV or any experimental agents.”


Primary objective:

The primary objective will be to determine the efficacy of NOVOTTF-200A in recurrent anaplastic astrocytoma patients (6-month progression-free survival)

Secondary objectives:

  • To evaluate the safety of NOVOTTF-200A in the subject population.

  • To evaluate the efficacy of NOVOTTF-200A in the subject population.

  • To see if the presence of ATRX, TERT promoter, IDH1 mutations, and/or MGMT promoter methylation, confers a better response to NOVOTTF-200A.

  • To determine if the treatment significantly modifies the patient’s quality of life. The sponsor will use the Functional Assessment of Cancer Therapy (FACT) questionnaires:
         1. FACT-Brain (FACT-Br)
         2. FACT-Cognitive Function (FACT-Cog)


Exploratory objectives:

  • To determine if the presence of pro-neural or mesenchymal phenotype (Cytoscan analysis) confers a better response to Novo-TTF.

  • To determine if the in vitro sensitivity of the glioma cells derived from patient specimens before and after the NOVOTTF-200A treatment correlates with the patient’s response to treatment.


Related clinical trials

Phase I/II trial of repeated super-selective intraarterial cerebral infusion of...

The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all...

Phase I-II study evaluating HSV-tK + valacyclovir gene therapy combination...

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy, and chemotherapy in newly...


Get new content delivered directly to your inbox.

bottom of page